S&P 500
7,582.20
+0.03%
Dow Jones
51,018.80
+0.58%
Nasdaq 100
30,344.40
+0.25%
Russell 2000
2,916.31
-0.54%
FTSE 100
10,378.60
-0.32%
Nikkei 225
66,231.90
+0.67%

Retail

Walgreen’s Sales Slide Continues

Photo of Paul Ausick
By Paul Ausick Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Walgreens_logo

Drug store giant Walgreen Co. (NYSE: WAG) announced this morning that December same-store sales fell 6.1% year-over-year, primarily due to the impact of generic drug sales replacing sales of higher-priced brand-name drugs. Total sales fell 4% from $6.99 billion last year to $6.71 billion.

Pharmacy sales in December fell 4.9%, and same-store pharmacy sales fell 8.9%. Pharmacy sales accounted for 56.7% of monthly sales.

Walgreen noted that a calendar shift was responsible for a negative impact of 2.3% on pharmacy sales, following a 2.9% drop in November. Sales of generic drugs as opposed to brand-name drugs cost the store 3.2% in comparable sales.

There was some positive news. The number of flu shots administered this year has risen from 5.3 million a year ago to 5.5 million. An increase in flu this year has boosted same-store drug sales by 1.4%, and the additional flu shots added 0.7% to sales in December.

Walgreen’s stock is down 0.8% this morning, at $37.50 in a 52-week range of $28.53 to $38.41, as virtually every metric reported today was down.

DISCLOSURE:
INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org). Advisory services are offered by SoFi Wealth LLC, an SEC-registered investment adviser. Information about SoFi Wealth’s advisory operations, services, and fees is set forth in SoFi Wealth’s current Form ADV Part 2 (Brochure), a copy of which is available upon request and at www.adviserinfo.sec.gov. Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 30 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees. Investing in alternative investments and/or strategies may not be suitable for all investors and involves unique risks, including the risk of loss. An investor should consider their individual circumstances and any investment information, such as a prospectus, prior to investing. Interval Funds are illiquid instruments, the ability to trade on your timeline may be restricted. Brokerage and Active investing products offered through SoFi Securities LLC, Member FINRA(www.finra.org) /SIPC(www.sipc.org). There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event. Options involve risks, including substantial risk of loss and the possibility an investor may lose the entire investment Before trading options please review the Characteristics and Risks of Standardized Options  Investing in an Initial Public Offering (IPO) involves substantial risk, including the risk of loss. Further, there are a variety of risk factors to consider when investing in an IPO, including but not limited to, unproven management, significant debt, and lack of operating history. For a comprehensive discussion of these risks please refer to SoFi Securities’ IPO Risk Disclosure Statement This should not be considered a recommendation to participate in IPOs and investors should carefully read the offering prospectus to determine whether an offering is consistent with their investment objectives, risk tolerance, and financial situation. New offerings generally have high demand and there are a limited number of shares available for distribution to participants. Many customers may not be allocated shares and share allocations may be significantly smaller than the shares requested in the customer’s initial offer (Indication of Interest). For more information on the allocation process please visit IPO Allocation.
Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Paul Ausick |

Walgreen’s Same-Store Sales Dive

Drug store giant Walgreen Co. (NYSE: WAG) announced this morning that November same-store sales fell 6.2% year-over-year, primarily due to…

Paul Ausick |

Walgreen Results Send Shares Sliding

courtesy of WalgreenWalgreen Co. (NYSE: WAG) reported first-quarter fiscal 2013 results before markets opened this morning. The drug store chain…

Why Walgreens Earnings Beat May Not Have Been Enough
Paul Ausick |

Why Walgreens Earnings Beat May Not Have Been Enough

The Dow's newest component, Walgreens Boots Alliance, reported quarterly earnings Thursday morning that beat estimates, but there were some weaknesses,…

Why Rite Aid Earnings Matter Less Than the Walgreens Merger
Paul Ausick |

Why Rite Aid Earnings Matter Less Than the Walgreens Merger

Rite Aid reported mixed second-quarter fiscal 2017 results before markets opened Thursday morning, but that may not matter as much…

Paul Ausick |

Walgreens Reports Drop in Same-store Sales (WAG, ESRX)

Pharmacy retailer Walgreens (NYSE: WAG) reported same-store sales for February were down -4.6% compared with February 2011. The number of…

Jon C. Ogg |

Research Hints At Rite Aid Buyout With 61% Upside to Target (RAD, WAG, ESRX)

Rite Aid Corp. (NYSE: RAD) has been a troubled stock in a difficult financial position for over a decade now. …

Clark Howard: $200 Walgreens Quote Became $22 at Cost Plus Drugs for This NC Man
Austin Smith |

Clark Howard: $200 Walgreens Quote Became $22 at Cost Plus Drugs for This NC Man

Gary from North Carolina walked into Walgreens to pick up a generic prescription and got quoted over $200 out of…

Rite Aid Stumbles as It Looks Forward to Merger With Walgreens
Paul Ausick |

Rite Aid Stumbles as It Looks Forward to Merger With Walgreens

Rite Aid reported disappointing first-quarter fiscal 2017 results before markets opened Thursday morning.

Paul Ausick |

Stein Mart’s March Same-Store Sales Surge

Retailers are announcing March U.S. same-store sales figures Thursday. Research firm Retail Metrics projected an overall gain of 1.1% year-over-year.

Top Gaining Stocks

Dell Technologies
DELL • Vol: 42,366,555
NetApp
NTAP • Vol: 15,911,807
ServiceNow
NOW • Vol: 68,243,561
IBM
IBM • Vol: 28,527,546
Hewlett Packard Enterprise
HPE • Vol: 86,996,387

Top Losing Stocks

Coterra Energy
CTRA • Vol: 73,319,495
Clorox
CLX • Vol: 4,744,001
ResMed
RMD • Vol: 3,526,686
Intel
INTC • Vol: 191,680,425
Skyworks Solutions
SWKS • Vol: 5,407,806